MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Summary

The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.

Conditions

• Acute Graft-versus-host Disease

Interventions

DRUG

CD25 monoclonal antibody

DRUG

calcineurin inhibitors

BIOLOGICAL

MSCs

Sponsors & Collaborators

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Third Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• Guangzhou General Hospital of Guangzhou Military Command

  collaborator OTHER

• Guangzhou First People's Hospital

  collaborator OTHER

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  collaborator OTHER

• Southern Medical University, China

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Huazhong University of Science and Technology

  collaborator OTHER

• Sun Yat-sen University

  collaborator OTHER

• Academy Military Medical Science, China

  collaborator INDUSTRY

• Nanfang Hospital, Southern Medical University

  lead OTHER

Principal Investigators

• Qifa Liu, MD · Nanfang Hospital, Southern Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

14 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-09-30

Primary Completion

2018-09-30

Completion

2018-12-31

Countries

• China

Study Locations